END OF LIFE TREATMENTS

That this House congratulates the National Institute for Health and Clinical Excellence (NICE) for introducing additional considerations for the appraisal of life extending, end of life treatments; warmly welcomes the positive outcomes for patients from these reforms; further welcomes the outcomes from one of the first such appraisals to use these additional considerations which resulted in a preliminary recommendation to make lenalidomide available for use in the NHS to treat multiple myeloma; further congratulates the patient groups who championed these reforms, including Myeloma UK and the Rarer Cancers Forum; recognises the significant contribution made by the recently-deceased Chief Executive of the Rarer Cancers Forum, Penny Wilson-Webb; and commends the manufacturers of lenalidomide, Celgene, for negotiating the pricing system which enabled NICE to make this positive recommendation.